Hematology-Oncology – Page 8

Recurrent Venous Thromboembolism After Isolated Distal DVT: Insights from the RIDTS Trial

By MedXY 07/07/2026

This article reviews the incidence and predictors of recurrent VTE following anticoagulation for isolated distal deep vein thrombosis, highlighting key risk factors and implications for treatment duration and patient management.

Hematology-Oncology news

Linperlisib Potentiates MUC1-Tn CAR T Cell Therapy by Suppressing the EGR1/DUSP2 Axis to Combat T-Cell Acute Lymphoblastic Leukemia

By MedXY 07/06/2026

This study highlights how linperlisib, a PI3Kδ inhibitor, enhances MUC1-Tn CAR T cell efficacy in T-ALL by preventing T cell exhaustion via suppression of the EGR1/DUSP2 pathway, improving anti-leukemic activity and persistence.

Hematology-Oncology news Pathology & Lab Medicine/Bệnh học

Engineering Single-Chain Variable Fragments to Identify Pathogenic Antibodies in Heparin-Induced Thrombocytopenia

By MedXY 07/06/2026

Development of engineered antibody fragments enables precise detection of pathogenic antibodies in heparin-induced thrombocytopenia, improving diagnosis and understanding of this immune-mediated blood disorder.

Hematology-Oncology Internal Medicine news

PASS: A Simplified Clinical Tool to Differentiate Acquired Aplastic Anemia from Inherited Bone Marrow Failure Syndromes in Adults

By MedXY 07/04/2026

The Predictive Aplastic Score System (PASS) accurately distinguishes acquired aplastic anemia from inherited bone marrow failure syndromes using seven clinical variables, enabling rapid diagnosis and improved treatment decisions in adults.

Hematology-Oncology news

Decoding Clonal Evolution and Immunophenotype in NPM1-Mutated AML through Single-Cell Multiomics

By MedXY 07/02/2026

Single-cell multiomic analysis reveals how genotype-immunophenotype relationships shape clonal evolution in NPM1-mutated acute myeloid leukemia, highlighting implications for prognosis and therapy response.

Hematology-Oncology news Oncology

Unified Conditioning and GVHD Prophylaxis with Fludarabine, Cyclophosphamide, and 2 Gy TBI plus Post-Transplant Cyclophosphamide in Elderly AML/MDS Patients Undergoing Haploidentical or Unrelated Donor Allo-SCT

By MedXY 06/30/2026

Fludarabine, cyclophosphamide, and low-dose TBI combined with post-transplant cyclophosphamide provide a safe and effective single platform for haploidentical and unrelated donor allo-SCT in older AML/MDS patients, showing favorable survival and GVHD outcomes.

Hematology-Oncology news Pathology & Lab Medicine

Decoding CD79B Expression Gradient in Diffuse Large B-Cell Lymphoma: Implications for Germinal Center B-Cell Differentiation and Therapeutic Targeting

By MedXY 06/30/2026

CD79B expression in diffuse large B-cell lymphoma (DLBCL) exhibits a distinct gradient aligned with cell-of-origin subtypes and germinal center B-cell differentiation stages, highlighting the biological basis for differential therapy responses.

Allergy & Immunology Hematology-Oncology news

Unraveling Immune Dysfunction in Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma: The Role of Systemic Antiviral Loss and Myeloid Suppression

By MedXY 06/30/2026

EBV-positive diffuse large B-cell lymphoma exhibits severe systemic antiviral T-cell impairments and a suppressive tumor microenvironment driven by LMP1, revealing novel immunobiological insights with therapeutic implications.

Hematology-Oncology news

Impact of Diagnosis-to-Treatment Interval on Outcomes in Follicular Lymphoma Undergoing Immunochemotherapy

By MedXY 06/30/2026

Shorter diagnosis-to-treatment intervals independently predict worse outcomes in follicular lymphoma treated with immunochemotherapy, highlighting a novel prognostic factor beyond existing risk indices.

Clinical Updates Gastroenterology Hematology-Oncology news

Fecal Calprotectin as a Biomarker for Diagnosis and Monitoring of Gastrointestinal Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation

By MedXY 06/25/2026

Fecal calprotectin offers a non-invasive, dynamic biomarker to predict, diagnose, and monitor GI-GVHD post-allo-HSCT, correlating with endoscopic severity and treatment response, but requires integrated clinical interpretation due to limited specificity.

Hematology-Oncology news

Enhancing Acute Myeloid Leukemia Treatment: Dual CDK2 and CDK4/6 Inhibition Targets Cell Cycle and Rb/E2F Signaling

By MedXY 06/25/2026

Dual inhibition of CDK2 and CDK4/6 demonstrates synergistic anti-leukemic effects in AML by suppressing the Rb/E2F axis, offering a promising therapeutic strategy to improve outcomes in this challenging hematologic malignancy.

Hematology-Oncology news

Unraveling Molecular Mechanisms in Chronic Myeloid Leukemia: Insights from the EURO-SKI Biomarker Study on Treatment-Free Remission and Relapse

By MedXY 06/25/2026

The EURO-SKI Biomarker Study elucidates molecular signatures and immune interactions underlying treatment-free remission and relapse in chronic myeloid leukemia patients discontinuing tyrosine kinase inhibitors, highlighting immune communication as key to sustained remission.

Allergy & Immunology Hematology-Oncology news

α-Gal Sensitization as a Cause of Severe Allergic Reactions in Group O Recipients of Group B/AB Plasma and Platelets

By MedXY 06/25/2026

Severe allergic transfusion reactions in group O recipients receiving group B or AB plasma or platelets are linked to IgE antibodies against the α-Gal epitope, highlighting a novel immunological mechanism and potential risk stratification approach.

Hematology-Oncology Internal Medicine news

Allogeneic Stem Cell Transplantation After 70: Japanese Registry Data Define Who May Benefit Most

By MedXY 06/19/2026

A Japanese registry study of 929 patients aged 70+ identified six predictors of worse survival after allo-HSCT and created a simple score that sharply stratified 2-year overall survival from 57.1% to 2.5%.

Hematology-Oncology news Pathology & Lab Medicine/Bệnh học

BRAF Mutations in AML: Rare, Biologically Distinct, and Linked to Poor Outcomes

By MedXY 06/19/2026

BRAF mutations occur in about 1% of AML and are usually non-V600 variants enriched in myelodysplasia-related disease. This cohort study found poor survival and suggested that current therapies, including venetoclax-based regimens, remain inadequate.

$Complement Activation May Define a Refractory Subset of Adult ITP$

Hematology-Oncology news Pathology & Lab Medicine/Bệnh học

Complement Activation May Define a Refractory Subset of Adult ITP

By MedXY 06/19/2026

Complement deposition on platelets identifies a biologically distinct subset of adult ITP associated with higher platelet turnover and more first-line treatment refractoriness.

Hematology-Oncology news OB/GYN & Women’s Health

GLP-1 Receptor Agonists May Outperform Bariatric Surgery in Obese Postmenopausal Breast Cancer Patients, Study Suggests

By MedXY 06/18/2026

A large real-world study found GLP-1 receptor agonists were associated with better survival and lower locoregional recurrence than bariatric surgery in postmenopausal women with obesity and breast cancer.

Cardiology Hematology-Oncology news

The Fibrinogen αC Region Promotes Arterial Thrombosis in Hypofibrinogenemia

By MedXY 06/10/2026

Low fibrinogen alone did not prevent arterial thrombosis in humans or mice, but loss of the fibrinogen αC region reduced clot formation. The study suggests fibrinogen structure, not just level, influences arterial thrombotic risk.

Clinical Updates Hematology-Oncology news

Fludarabine Dose Intensity, Lymphodepletion Biology, and Product-Specific Outcomes in Large B-Cell Lymphoma CAR-T Therapy: Interpreting the 2026 EBMT Registry Analysis

By MedXY 06/09/2026

A large EBMT registry study suggests that escalating fludarabine during lymphodepletion does not improve tisagenlecleucel outcomes in LBCL and may worsen survival, while axicabtagene ciloleucel retains superior efficacy at standard dosing but with more neurotoxicity.

Hematology-Oncology news Oncology

Pre-diagnostic Clonal Hematopoiesis Raises Risk of Second Cancers in Patients With Primary Cancer

By MedXY 06/08/2026

Patients with primary cancer who had pre-diagnostic CHIP faced a higher risk of second cancers, especially blood cancers. The findings suggest CHIP may help identify survivors who need closer long-term monitoring.